Rilmenidine-d4

• Description:

  Rilmenidine-d4 is the deuterium labeled Rilmenidine. Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy. Rilmenidine acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport. Rilmenidine modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells[1][2][3].

• UNSPSC:

  12352005

• Target:

  Adrenergic Receptor; Apoptosis; Autophagy; Imidazoline Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling; Others

• Field of Research:

  Cancer; Cardiovascular Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C1([2H])C([2H])(OC(NC(C2CC2)C3CC3)=N1)[2H]

• Molecular Formula:

  C10H12D4N2O

• Molecular Weight:

  184.27

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Reid JL. Rilmenidine: a clinical overview. Am J Hypertens. 2000;13 (6 Pt 2) :106S-111S.|[3]Srdic-Rajic T, et al. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. Eur J Pharm Sci. 2016;81:172-180.|[4]Rose C, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet. 2010;19 (11) :2144-2153.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  85047-14-9